Same Name, Different Chemical: The Hidden Salt-Form Trap in Peptide Testing

A vial arrives at the laboratory labeled “BPC-157.” The name appears specific. Analytically, it may not be.

Does the vial contain the peptide sequence expected by the purchaser? Is the material a non-salt form, an acetate salt, a trifluoroacetate salt, a chloride salt, or a mixture of counterions? Does the labeled amount refer to the total lyophilized powder, the complete peptide salt, or only the peptide moiety? Was the reference material used for testing assigned on the same basis?

These are not minor documentation questions. They determine what substance is being tested, what the analytical result means, and whether the reported amount answers the question the customer intended to ask.

In briefing materials prepared for the July 23–24, 2026 meeting of the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee, FDA reviewers identified inconsistent descriptions of several peptide-related bulk drug substances, including BPC-157, KPV, and TB-500. Some nomination materials referred to a “free base,” others to an acetate form, and some used a common name without sufficient chemical information to establish which substance was actually being discussed. FDA evaluated the free-base and acetate forms as separate bulk drug substances.¹–⁴

That distinction matters. A peptide and one of its salt forms may contain the same peptide moiety, but they are not complete, interchangeable descriptions of the same material. Counterion composition can affect formula weight, the amount of peptide represented by each milligram of powder, and physical properties such as solubility, stability, hygroscopicity, and handling.

Before a laboratory can evaluate quality, it must first define the material and the quantity intended to be measured.

One Common Name Can Describe More Than One Material

Peptides contain ionizable functional groups. Depending on the amino-acid sequence, terminal groups, modifications, and surrounding pH, a peptide may carry a positive charge, a negative charge, or both positive and negative charges at different sites.

Oppositely charged ions may be associated with the peptide to maintain electrical neutrality. These accompanying ions are called counterions.

For peptide preparations carrying net positive charge, common anionic counterions include:

• Acetate
• Trifluoroacetate, commonly abbreviated TFA
• Chloride

Peptides carrying net negative charge may instead be associated with cationic counterions such as sodium or ammonium. A material may also contain mixed counterions or counterion levels that do not correspond to a simple, fixed whole-number ratio.

The counterion composition remaining after peptide synthesis, purification, counterion exchange, concentration, and lyophilization depends on the manufacturing process. A supplier’s statement that a material is “acetate” does not, by itself, establish how much acetate is present in that specific lot.

This is also why the term “free base” should be used carefully for peptides. Peptides may contain several acidic and basic groups, and their charge state changes with pH. FDA uses the term “free base” in its 2026 briefing documents, but the term should be interpreted together with the molecular formula, sequence, terminal groups, modifications, and analytical definition provided for the material.

A defensible identification should address, as applicable:

• Amino-acid sequence
• N-terminal and C-terminal forms
• Covalent modifications
• Disulfide connectivity, when relevant
• Salt or counterion designation
• Counterion composition or stoichiometry
• Water and residual-solvent content
• The basis on which peptide content is reported

The common name on the vial is only the beginning of the identity question.

FDA’s Review Illustrates the Nomenclature Problem

FDA’s July 2026 briefing documents describe BPC-157, KPV, and TB-500 as common names rather than formally assigned United States Adopted Names. FDA reported encountering salts, derivatives, and, in some instances, different active moieties marketed under the same common name.

The agency also noted that inconsistent naming creates an analytical problem because it may be unclear which bulk drug substance a reference standard, Certificate of Analysis, publication, or supplier specification actually represents.²–⁴

For example, FDA reported that the KPV nomination materials did not consistently establish whether the nominated substance was KPV free base or KPV acetate. FDA treated those forms as distinct bulk drug substances and listed different molecular formulas and molecular weights for them.³

FDA described similar inconsistencies for TB-500. The nomination, accompanying CoA, CAS information, formula, molecular weight, and substance name did not consistently identify the same chemical form.⁴

For BPC-157, FDA reported that nomination materials referred to BPC-157 acetate while portions of the submitted chemical information corresponded to the free-base form. FDA’s table also represented the acetate contribution as variable rather than assigning a single fixed acetate stoichiometry and molecular weight.²

These examples demonstrate a basic analytical principle: a result cannot be interpreted correctly unless the analyte and measurand have been defined clearly.

The Molecular-Weight Difference Is Real

The effect of salt form can be seen directly in molecular weight.

FDA’s KPV evaluation lists:

FDA’s TB-500 evaluation lists:

The nominal molecular-weight differences are approximately 60.1 g/mol, corresponding to the acetic-acid component represented in FDA’s formulas.³˒⁴

These examples are not universal conversion factors. The actual counterion contribution depends on:

• The peptide’s ionizable sites
• The counterion identity
• Salt stoichiometry
• Mixed-counterion composition
• Residual water
• Residual solvents
• Other inorganic or nonvolatile components
• The lot-specific analytical composition

BPC-157 illustrates this limitation particularly well. FDA represented the acetate form as:

C₆₂H₉₈N₁₆O₂₂·X(C₂H₄O₂)

FDA did not assign a single molecular weight because the value of X, representing the acetate contribution, was not fixed in the source information.²

One milligram of total peptide salt is therefore not automatically equivalent to one milligram of peptide moiety.

Gross Powder Weight Is Not Peptide Content

A lyophilized vial can contain more than the peptide itself. Depending on how the material was produced or formulated, the vial may contain:

• Peptide
• Counterions
• Water
• Residual solvents
• Buffer salts
• Bulking agents
• Stabilizers
• Other excipients
• Process-related impurities
• Degradation products

A gravimetric vial-fill result measures the total material placed into the vial. It does not independently determine how much of that material is peptide.

Consider a vial containing 10.0 mg of lyophilized powder. That number alone does not establish that the vial contains 10.0 mg of peptide moiety. If the powder contains counterions, water, residual solvent, or excipients, those components contribute to the total mass.

The reporting basis therefore matters. A quantitative result might be expressed as:

• Total lyophilized material
• Complete peptide salt
• Peptide moiety
• Free-peptide equivalent
• As-received content
• Dry-basis content
• Anhydrous-basis content
• Content corrected for reference-standard potency

Those are not necessarily equivalent results.

Why Mass Spectrometry Does Not Answer Every Composition Question

Mass spectrometry is one of the most powerful tools available for peptide characterization. High-resolution LC-MS can determine whether the observed peptide ion has a molecular mass consistent with the proposed molecular composition.

Tandem mass spectrometry may provide additional sequence-level evidence by examining fragmentation patterns. Depending on the peptide and method, MS/MS may help identify truncations, substitutions, terminal modifications, or other structural differences.

However, a correct intact mass does not automatically establish the complete identity or composition of the powder.

Intact-mass analysis may not independently distinguish:

• Leucine from isoleucine
• Certain sequence permutations
• Some isobaric substitutions
• All stereochemical differences
• Every positional isomer
• Counterion identity or quantity
• Water content
• Residual-solvent content
• The peptide’s mass fraction in the powder

Under common reversed-phase LC-electrospray MS conditions, counterions may dissociate from the peptide, elute separately, be removed during chromatographic separation, appear as variable adducts, or influence ionization rather than remain attached as a single intact salt species.

The mass spectrum can therefore provide strong evidence for the peptide moiety while leaving a separate question unanswered: what else is contributing to the sample’s total mass?

That is not a weakness of mass spectrometry. It is a reminder that every analytical method answers a defined question.

No single analytical result should be interpreted beyond what the method was designed and validated to establish.

Chromatographic Area Purity Is Not Peptide Content by Mass

This distinction is especially important when interpreting a “99% purity” claim.

A reversed-phase HPLC result is commonly calculated by area normalization. Under this approach, the area of the main chromatographic peak is divided by the combined area of the peaks included in the integration and expressed as a percentage.

A more precise description would be:

The main peak represented 99.0% of the integrated chromatographic response included under the specified RP-HPLC method, detection wavelength, and integration parameters.

That result may be useful for evaluating chromatographic purity and peptide-related impurities detected by the procedure.

It does not necessarily mean that 99.0% of the powder’s mass is peptide.

Several factors explain the difference:

1. Counterions may not be detected under the peptide HPLC conditions.
   Acetate, chloride, and other ions may not produce a meaningful response at the UV wavelength used to detect peptide bonds.
2. Water does not appear as a peptide impurity peak.
   Water can contribute materially to sample mass while remaining invisible to the RP-HPLC purity calculation.
3. Residual solvents may not be represented.
   Many solvents require a separate gas-chromatographic or other targeted method.
4. Inorganic salts may not be detected.
   Sodium, chloride, phosphate, or other ionic components may not appear in the peptide chromatogram.
5. Not every impurity has the same detector response.
   Area normalization assumes, explicitly or implicitly, that detector response is sufficiently comparable for the intended interpretation. Peptide impurities with different chromophores or structures may have different response factors.
6. Not every component is necessarily resolved.
   Coelution can cause an impurity to be included within the main-peak area.
7. Integration parameters affect the result.
   Peak thresholds, baseline selection, excluded peaks, and manual integration decisions can change the reported area percentage.

A peptide salt can legitimately produce a chromatographic area purity of 99% or greater. The analytical error occurs when that number is represented as 99% peptide by mass without an appropriate quantitative assay and supporting composition data.

“99% HPLC area purity” and “99% peptide content by mass” are different claims.

The Reference-Material Problem

Analytical testing depends on suitable reference materials. A laboratory may compare retention time, UV response, spectral characteristics, exact mass, fragmentation, or quantitative response against a material whose identity and assigned value are known.

The word “standard,” however, does not guarantee suitability.

A reference material may be adequate for one purpose and inadequate for another.

For example, a material may be suitable for supporting retention-time or intact-mass identity of the peptide moiety even when its counterion composition differs from the sample. That same material may be unsuitable for a mass-based assay unless its assigned content and calculation basis are adequately characterized.

For quantitative testing, the laboratory should understand, as applicable:

• The reference material’s complete identity
• Sequence and terminal groups
• Covalent modifications
• Salt or counterion form
• Assigned purity or content
• Water content
• Residual-solvent content
• Counterion contribution
• Whether the assigned value is area purity or mass fraction
• Uncertainty associated with the assigned value
• The basis on which the standard concentration is prepared

Suppose a laboratory weighs 10.0 mg of a reference material and assumes that all 10.0 mg is peptide. If the material contains water, acetate, TFA, or other mass contributors, the prepared peptide concentration may be lower than assumed.

The calibration curve may appear linear, system suitability may pass, and the instrument may function correctly, yet the final quantity can still be biased because the reference concentration was assigned incorrectly.

This is the central risk of an ambiguously defined measurand: the analytical procedure may operate exactly as designed while answering the wrong quantitative question.

Counterion Exchange Is Not Merely a Label Change

Synthetic peptides are frequently purified using trifluoroacetic acid or TFA-containing mobile phases. The resulting material may contain trifluoroacetate counterions.

A manufacturer may subsequently perform a counterion-exchange process intended to replace TFA with acetate, chloride, or another ion.

That process changes the material’s counterion composition. Even when the peptide’s covalent amino-acid sequence remains unchanged, counterion exchange may affect:

• Formula weight
• Peptide mass fraction
• Solubility
• Hygroscopicity
• Secondary structure
• Aggregation behavior
• Stability
• Reconstitution behavior
• Formulation compatibility
• Biological-assay performance

An acetate form is not automatically superior to a TFA form, and a TFA form is not automatically unsuitable. The effect depends on the peptide, formulation, intended use, counterion level, and applicable quality requirements.

A defensible exchange process should demonstrate:

• That the intended counterion is present
• That the original counterion was reduced to an established level
• The lot-specific quantity of each relevant counterion
• That peptide identity and integrity were maintained
• That the reported peptide quantity uses the correct molecular and mass basis

A supplier’s statement that a peptide was “converted to acetate” should be supported by counterion-specific analytical evidence.

Salt Form Can Affect More Than the Calculation

Salt-form differences are not limited to molecular-weight corrections.

FDA’s briefing documents note that free-base, salt, and ester forms may have different physical, chemical, pharmacokinetic, or pharmacodynamic characteristics. Potentially affected properties include solubility, permeability, melting point, stability, and flow behavior.²–⁴

The magnitude and direction of these effects are peptide- and formulation-specific.

Two materials sold under the same common peptide name may therefore behave differently during:

• Reconstitution
• Filtration
• Sterile processing
• Storage
• Freeze-thaw cycling
• Chromatographic analysis
• Biological testing
• Formulation development

Instructions developed for one salt form should not automatically be applied to another without supporting data.

What a Useful Certificate of Analysis Should Tell You

A professionally formatted Certificate of Analysis can still be analytically incomplete.

The necessary tests depend on the material, intended use, specification, and claims being made. However, when identity, salt form, and peptide quantity are important, the CoA or supporting analytical package should clearly address the following.

Defined analyte identity

The report should identify the material using more than a marketplace name. Relevant information may include:

• Peptide sequence
• Terminal groups
• Covalent modifications
• Disulfide connectivity
• Salt or counterion designation
• Molecular formula
• Theoretical molecular mass
• Applicable identifiers, used cautiously and verified for the stated form

Lot-specific traceability

The lot number on the vial, sample submission, analytical records, and final report should correspond.

Identity evidence

The report should identify the analytical procedure used to support identity, such as high-resolution LC-MS or LC-MS/MS, and state what the result establishes.

“Identity confirmed” should not be based solely on a nonspecific HPLC retention time unless the method and available evidence support that conclusion.

Purity method and reporting basis

The word “purity” should be accompanied by sufficient information to interpret it, such as:

• RP-HPLC or UPLC
• Detection wavelength
• Main-peak area percentage
• Relevant integration basis
• Whether the method is selective for known impurities
• Whether stability-indicating capability has been demonstrated

A method should not be described as stability-indicating merely because it is chromatographic. Stability-indicating capability requires evidence that the analyte can be distinguished from relevant degradation products under the established procedure.

Counterion information

If the material is represented as acetate, TFA, chloride, or another salt, the basis for that designation should be documented.

When net peptide content matters, quantitative counterion analysis may be necessary.

Water and other mass contributors

Water, residual solvents, inorganic residue, excipients, and other components should be considered when results are used for mass balance, formulation, or dose-related calculations.

Reference-material suitability

The report or validation records should establish that the reference material is suitable for the specific identity or quantitative procedure.

The reference material’s source, lot, characterization, assigned value, and calculation basis should be documented.

Calculation and reporting basis

A quantitative result should state whether it is reported:

• As received
• On a dry basis
• On an anhydrous basis
• As the complete salt
• As peptide moiety
• As free-peptide equivalent
• After correction for reference-standard assigned content
• After correction for water, counterions, or residual solvents

Without this information, a large, bold purity percentage may have no clear relationship to the amount of peptide actually present.

A Defensible Analytical Strategy Uses Complementary Methods

There is no universal test panel that is appropriate for every peptide and every intended use. A defensible characterization strategy is selected from the analytical questions that must be answered.

Additional testing may be needed for particular materials or intended uses, including:

• Size-exclusion chromatography for aggregates
• Amino-acid analysis
• Optical rotation or chiral analysis
• Disulfide mapping
• Host-cell protein or DNA testing for recombinant products
• Bioburden
• Bacterial endotoxins
• Sterility
• Particulate matter
• Elemental impurities
• Biological activity or potency

The method set should be selected based on the sample, manufacturing process, intended use, specification, and decision the results are expected to support.

What FDA’s July 2026 Review Is Signaling

The July 23–24, 2026 PCAC meeting concerns whether specified bulk drug substances should be included on the 503A Bulks List.

In its briefing documents, FDA states that its evaluation criteria weigh against placing the evaluated free-base and acetate forms of BPC-157, KPV, and TB-500 on that list. The committee provides nonbinding recommendations, and FDA states that it will not make a final determination until the advisory-committee process has been considered and the reviews are finalized.¹–⁴

Vanguard Laboratory does not take a position in this article on prescribing, compounding, or clinical use. The analytical lesson is narrower.

FDA reviewers encountered submissions in which common names, salt forms, formulas, molecular weights, CoAs, and reference materials did not consistently describe the same chemical entity.

That made it more difficult to:

• Determine which substance had been nominated
• Compare information across sources
• Evaluate reference standards
• Interpret Certificates of Analysis
• Assess physical and chemical characterization
• Determine whether different documents addressed the same material

This is more than a paperwork problem. It is a failure to define the measurand: the specific quantity and chemical entity intended to be measured.

If the analyte or reporting basis is poorly defined, every downstream number becomes harder to interpret.

Vanguard’s Analytical Approach: Define First, Measure Second

Defensible peptide characterization requires more than a chromatogram and a percentage.

It requires:

• A clearly defined analyte
• Methods selected for the intended analytical question
• Suitable and appropriately characterized reference materials
• Lot-specific traceability
• A stated calculation basis
• Reporting that distinguishes peptide identity, chromatographic area purity, counterion composition, water content, and quantitative peptide assay

Those measurements are related, but they are not interchangeable.

The most important question is not simply:

Does the CoA say 99%?

The more useful questions are:

Ninety-nine percent of what?

Measured by which analytical procedure?

Calculated from which reference material?

Reported on what mass basis?

When a vial is labeled only “BPC-157,” “KPV,” or “TB-500,” significant chemistry may remain undefined. FDA’s 2026 briefing materials provide a timely reminder that rigorous testing begins by defining the material before attempting to quantify it.

Need a clearer analytical picture of a peptide material? Contact Vanguard Laboratory to discuss lot-specific identity, chromatographic purity, counterion, water, and quantitative assay requirements.

This article addresses analytical characterization and reporting. It does not constitute medical advice, endorse the clinical use of any substance, or imply that a substance, compounded preparation, or laboratory-tested material is FDA approved.

References

1. U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — Introduction.
2. U.S. Food and Drug Administration. FDA Briefing Document for BPC-157-Related Bulk Drug Substances: BPC-157 Free Base and BPC-157 Acetate.
3. U.S. Food and Drug Administration. FDA Briefing Document for KPV-Related Bulk Drug Substances: KPV Free Base and KPV Acetate.
4. U.S. Food and Drug Administration. FDA Briefing Document for TB-500-Related Bulk Drug Substances: TB-500 Free Base and TB-500 Acetate.